Novavax announced extended durability of protection against infection and disease in UK COVID-19 vaccine phase 3 clinical Trial
On Feb. 24, 2022, Novavax shared extended analysis from its pivotal Phase 3 clinical trial conducted in the…
On Feb. 24, 2022, Novavax shared extended analysis from its pivotal Phase 3 clinical trial conducted in the…
On Feb. 24, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
On Feb. 23, 2022, Moderna and Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated…
On Feb. 23, 2022, Novavax announced the first doses of Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) had begun shipping…
On Feb. 23, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
On Feb. 22, 2022, Sorrento Therapeutics announced that additional preclinical results demonstrate broad spectrum COVISHIELD (STI-9167) neutralizing activity…
On Feb. 22, 2022, Moderna announced a distribution service agreement with Adium Pharma, a leading private Latin American…
On Feb. 22, 2022, Washington University in St. Louis announced that a blood test developed at the University’s…
On Mar. 22, 2022, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
On Feb. 1, 2022, University of Virginia Cancer Center announced it had been awarded a Comprehensive Cancer Center…
On Feb. 19, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
On Feb. 18, 2022, the U.S. Centers for Disease Control and Prevention (CDC) released the 2022 recommended immunization…
On Feb. 17, 2022, Novavax announced that Health Canada had granted authorization for Nuvaxovid COVID-19 Vaccine (Recombinant protein,…
On Feb. 17, 2022, after studying blood samples from 244 patients hospitalized for COVID-19, a group of researchers,…
On Feb. 17, 2022, Resverlogix announced that the first Brazilian site had been initiated for its Phase 2b…
On Feb. 16, 2022, Moderna announced that the Therapeutic Goods Administration in Australia had granted provisional registration for…
On Feb. 16, 2022, the McKelvey School of Engineering at Washington University in St. Louis, announced the lab of…
On Feb. 15, 2022, Pfizer announced that the European Medicines Agency had approved the companyメs 20-valent pneumococcal conjugate…
On Feb. 15, 2022, a woman with HIV who received a cord blood stem cell transplant to treat…
On Feb. 14, 2022, Novavax announced that the Singapore Health Sciences Authority (HSA) had issued interim authorization for…
On Feb. 14, 2022, Novavax announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional…
On Feb. 14, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
On Feb. 14, 2022, The U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspective Service (APHIS) announced…
On Feb. 12, 2022, China’s medical products regulator announced that it had given conditional approval for Pfizer’s COVID-19…
On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…
On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…
On Feb. 10, 2022, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness…
On Feb. 9, 2022, the Indiana Department of Health confirmed that a case of H5N1 highly pathogenic avian…
On Feb. 8, 2022, Moderna announced a new supply agreement with the government of Colombia for 10.8 million…
On Feb. 8, 2022, Merck and Ridgeback Biotherapeutics announced that a total of 3.1 million courses of molnupiravir,…